Where Computational Design
Meets Molecular Discovery

The Glycoenzyme
Platform

It unites complex enzyme expression, multistep glycosylation pathway engineering, and computational modelling into a modular system for producing and analysing glycoenzymes and glycoconjugates.

Through this platform, Struenodo enables:

• Rapid enzyme characterisation and optimisation using advanced simulations and assay systems.

• Custom glycosylation pathways for vaccine, therapeutic and agrochemical applications.

• Standardised, reproducible production of glycoconjugates at scale.

UGC 2.0 – Continuous
Glycosyltransferase Assay

One of our core innovations is the Universal Glycosyltransferase Continuous (UGC 2.0) Assay, a high-throughput system that measures enzyme activity in real time.

This proprietary platform accelerates discovery by:

• Simplifying glycosyltransferase screening.

• Reducing cost and variability in enzyme validation.

• Enabling inhibitor discovery for drug development.

UGC 2.0 sets a new benchmark in assay precision – turning complex enzymatic analysis into a streamlined, data-rich process.

Cell-Free
Glycosylation Platform

Our cell-free glycosylation system allows the controlled synthesis of glycopeptides and glycoconjugates without living cells, eliminating costly precursors and scalability constraints.

It offers:

• Faster, cleaner biosynthesis compared to traditional cell-based methods.

• Customisable glycan structures on-demand.

• Compatibility with GMP and biopharmaceutical production pipelines.

This innovation opens new possibilities for developing vaccines, therapeutic proteins and diagnostic reagents with defined glycan profiles.

From Research to
Real-World Impact

Struenodo bridges the gap between academic research and industrial application.

Our work fuels:

• Drug discovery through glycoenzyme inhibitor screening.

• Next-generation vaccines based on glycopeptide libraries.

• Diagnostics and biosimilarity testing powered by precise glycoanalysis.

• Agrochemical innovation through engineered peptide and enzyme systems.

We do not just study molecules – we build technologies that turn molecular understanding into measurable global impact.

Computational Discovery
& Molecular Modelling

Our propriety reaction dynamics Free Energy based methods are used to discover enzymatic catalytic mechanisms that inform inhibitor/drug design.

Using docking, molecular dynamics, and AI-assisted modelling, we explore enzyme-substrate interactions and design novel inhibitors.

These computational insights guide experimental validation – saving time, reducing cost and driving smarter innovation.